Thursday, April 3, 2025

AZmed Gains Two FDA Clearances for AI Chest X-ray

Related stories

Cyberhaven secures $100M Series D for AI data security

Cyberhaven, a leader in data detection and response (DDR),...

Kong AI Gateway Unveils Advanced AI Governance Tools

Kong Inc., a pioneer in cloud API technologies, has...

Informatica Launches AI Cloud Integration & MDM

New generative AI-powered features boost developer productivity, accelerate enterprise...

Skai Launches Celeste AI, a GenAI Agent for Commerce Media

Skai, a leader in omnichannel commerce media solutions, has...

Centrilogic & CrewAI Partner to Boost AI Adoption in Canada

Centrilogic, a global provider of IT transformation solutions, has...
spot_imgspot_img

AZmed, one of the leading AI companies in medical imaging, announced that it has received two new U.S. Food and Drug Administration (FDA) clearances for its AI tool AZchest. The clearances include applications intended to assist radiologists in the interpretation and detection of chest X-rays for lung nodules and triage capabilities for pneumothorax and pleural effusion.

A standalone study on chest X-rays showed that AZchest has extremely high sensitivity in detecting lung nodules, at 88.47%, associated with a high specificity of 82.94%. In a controlled multi-reader multi-case trial, experienced radiologists interpreted a standardized set of chest X-rays both with and without the assistance of AZchest. When aided by AZchest, the sensitivity increased by 10%, reaching 89.35%. The AUC also increased by 5%.

Also Read: Techcyte Launches Fusion, a Unified Digital Pathology Platform

Regarding the triaging of pneumothorax and pleural effusion, the algorithm also confirmed its high detection performance. The sensitivity and AUC for pneumothorax and pleural effusion were 93.79% / 98.57% and 91.34% / 98.30%, respectively.

These results make AZchest one of the most effective AI tools now available in the United States, offering a quantifiable diagnostic advantage in real clinical practice and supporting the detection of cancer at early stages. The performances also sustain AZmed’s scientific reputation and clinical integrity in the medical imaging industry, and this validated capability supports the potential of AZchest to help reduce workload on radiologists.

“We are proud to add two new FDA clearances to our portfolio. Our deep learning algorithms are designed to rapidly and accurately detect abnormalities, thereby ensuring that critical cases are flagged for clinical review promptly,” said Julien VIDAL, CEO of AZmed.

Source: PRNewswire

Subscribe

- Never miss a story with notifications


    Latest stories

    spot_img